Several months ago, FHI Clinical began recruiting scientific and technological experts to join our newly formed panel of Scientific Advisory Experts, which was created to promote best practices, build alliances and spur innovation in the clinical trials research field. Today, we are pleased to announce that we have appointed five new members. Please join me in welcoming:
Vice President, Global Strategy
- Kevin Hurley
Mr. Hurley brings extensive regulatory expertise from his experience in pharmaceutical and biotech companies and technical and consulting roles.
- Dr. Kelly McKee, MD, MPH
In both his current role in the pharmaceutical industry and previous role as a research virologist and immunologist in the United States Army, Dr. McKee developed expertise that spans vaccines, respiratory viral infections, emerging diseases and sexually transmitted diseases.
- Dr. John Schieffelin, MD, MSPH
Dr. Schieffelin’s scientific and clinical research has covered the natural history, clinical care and immunology of viral hemorrhagic fevers, including those caused by flaviviruses, such as dengue and Zika, as well as Lassa fever and Ebola.
- Dr. Lucas Tina, MBChB, MSc
Dr. Tina’s experience spans successful drug and vaccine trials for neglected diseases and emerging infectious diseases, including malaria and polio.
- Dr. Christopher T. Woods, MD, MPH, FIDSA
Dr. Woods’s career has focused on epidemiology, genomics and precision medicine in infectious diseases.